Weiwei Chen

Dr. Weiwei Chen


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2025 in mSystems
Verified
Journal Article
Open access
QHQiuyao Hao
Qiuyao Hao
FHFei Huang
Fei Huang
LCLiangzheng Chang
Liangzheng Chang
HDHongyuan Dai
Hongyuan Dai
WCWeiwei Chen
Weiwei Chen
YZYun-Huan Zhen
Yun-Huan Zhen
Gut microbiota dysbiosis critically contributes to colitis-associated colorectal cancer (CAC) pathogenesis, positioning microbial modulation as a promising therapeutic strategy. Weissella cibaria ( W. cibaria ) is an emerging probiotic with potential cancer-inhibiting effects. This study investigates the anti-tumorigenic potential of W. cibaria in an azoxymethane/dextran sulfate sodium-induced CAC murine model. Mice were orally administered W. cibaria every 2 days from the beginning of the model construction until the end of the experiment. The study demonstrated significant changes in the gut microbiota of CAC mice, with a significant increase in the relative abundance of Lactobacillaceae . Supplementation with W. cibaria restored the intestinal barrier and significantly reduced the relative abundance of Lactobacillaceae in the gut microbiota. The changes in the gut microbiota reduced bile salt hydrolase activity and unconjugated bile acid (BA), reversing tumorigenesis in CAC mice. Changes in intestinal BA after W. cibaria supplementation upregulated farnesoid X receptor (FXR) expression in the intestine of CAC mice and inhibited the nuclear factor kappa-B pathway. Our findings establish that W. cibaria mitigates CAC progression through the gut microbiota-BA-FXR axis, providing mechanistic evidence for its probiotic application in CAC prevention and therapy. IMPORTANCE: Chronic gut inflammation driven by microbiota dysbiosis is a pivotal contributor to colitis-associated colorectal cancer (CAC) pathogenesis. Emerging evidence highlights Weissella cibaria ( W. cibaria) as a promising anti-colorectal cancer agent (Y. Du, L. Liu, W. Yan, Y. Li, et al., Sci Rep 13:21117, 2023, https://doi.org/10.1038/s41598-023-47943-7 ; S. Ahmed, S. Singh, V. Singh, K. D. Roberts, et al., Microorganisms 10:2427, 2022, https://doi.org/10.3390/microorganisms10122427 ), yet its role in CAC remains unexplored. To address this gap, we investigated the inhibitory effects of W. cibaria on CAC development in vivo and elucidated its underlying mechanisms. Our results demonstrated that oral administration of W. cibaria significantly reshaped gut microbial communities and activated bile acid (BA)-related metabolic pathways. Subsequent mechanistic studies revealed that microbiota remodeling by W. cibaria altered intestinal BA composition, particularly activating the farnesoid X receptor (FXR). FXR activation mediated by these BA shifts was identified as a critical suppressor of tumorigenesis, establishing W. cibaria as a novel probiotic capable of attenuating CAC progression. Collectively, this study uncovers a protective axis linking W. cibaria -driven microbiota modulation, BA metabolism change, and FXR-dependent tumor suppression, providing experimental evidence for probiotic-based CAC intervention strategies.

13 October 2020 in Oncology Reports
Verified
Journal Article
Open access
PDF file
RYRuirong Yi
Ruirong Yi
YOYoshifumi Ohno
Yoshifumi Ohno
ZTZheng Tian
Zheng Tian
SGShuhan Guo
Shuhan Guo
WCWeiwei Chen
Weiwei Chen
HSHiroshi Shirasawa
Hiroshi Shirasawa
Targeting cell‑cycle regulation to hinder cancer cell proliferation is a promising anticancer strategy. The present study investigated the effects of a novel sulfonamide, CCL113, on cell cycle progression in cancer cell lines (HeLa and HepG2), a noncancerous cell line (Vero) and a normal human fibroblast cell line (TIG‑1‑20). The present results showed that treatment with CCL113 significantly decreased the viability of the cancer cells. FACS analyses showed that CCL113 treatment increased the proportion of cancerous and noncancerous cells in the G2/M phase. Analyses of cell cycle regulatory proteins showed that CCL113 treatment inhibited the activity of CDK1 in HeLa cells, possibly due to the decrease in the level of Cdc25B/C proteins and arrest in the M phase. Using time‑lapse imaging‑assisted analyses of HeLa and Vero cells expressing fluorescent ubiquitination‑based cell cycle indicator (FUCCI), it was observed that CCL113 treatment led to a prolonged G2 phase at the G2/M checkpoint and arrest in the M phase in both cell lines. This possibly activated the DNA damage response in noncancerous cells, while inducing mitotic arrest leading to apoptosis in the cancer cells. The results of molecular docking studies suggested that CCL113 might have the potential to bind to the taxol‑binding site on β‑tubulin. In conclusion, CCL113 holds potential as a reliable anticancer drug due to its ability to induce mitotic arrest followed by apoptosis of cancer cells and to activate the DNA damage response in noncancerous cells, thereby facilitating exit from the cell cycle.

29 June 2024 in BMC Cancer
Verified
Journal Article
Open access
XLXiaoqin Liu
Xiaoqin Liu
YWYan Wang
Yan Wang
WWWenling Wang
Wenling Wang
HDHongming Dong
Hongming Dong
GWGang Wang
Gang Wang
WCWeiwei Chen
Weiwei Chen
Background and aims: The cardiotoxicity related to 5-Fluorouracil (5-FU) in cancer patients has garnered widespread attention. The systemic immune-inflammation index (SII) has recently been identified as a novel predictive marker for the development of cardiovascular illnesses in individuals without pre-existing health conditions. However, it remains unclear whether the levels of SII are linked to cardiotoxicity related to 5-FU. This retrospective study aims to fill this knowledge gap by examining the correlation between SII and cardiotoxicity related to 5-FU in a colorectal cancer cohort. Methods: The study comprised colorectal cancer patients who received 5-FU-based chemotherapy at the affiliated cancer hospital of Guizhou Medical University between January 1, 2018 and December 31, 2020. After adjustment for confounders and stratification by tertiles of the interactive factor, linear regression analyses, curve fitting and threshold effect analyses were conducted. Results: Of the 754 patients included final analysis, approximately 21% (n = 156) of them ultimately experienced cardiotoxicity related to 5-FU. Monocytes (M) was found as an influential element in the interaction between SII and cardiotoxicity related to 5-FU. In the low tertile of M (T1: M ≤ 0.38 × 109/L), increasing log SII was positively correlated with cardiotoxicity related to 5-FU (Odds Ratio [OR], 8.04; 95% confidence interval [95%CI], 1.68 to 38.56). However, a curvilinear relationship between log SII and cardiotoxicity was observed in the middle tertile of M (T2: 0.38 < M ≤ 0.52 × 109/L). An increase in log SII above 1.37 was shown to be associated with a decreased risk of cardiotoxicity (OR, 0.14; 95%CI, 0.02 to 0.88), indicating a threshold effect. In the high tertile of M (T3: M > 0.52 × 109/L), there was a tendency towards a negative linear correlation between the log SII and cardiotoxicity was observed (OR, 0.85; 95%CI, 0.37 to 1.98). Conclusion: Our findings suggest that SII may serve as a potential biomarker for predicting cardiotoxicity related to 5-FU in colorectal cancer patients. SII is an independent risk factor for cardiotoxicity related to 5-FU with low monocytes levels (T1). Conversely, in the middle monocytes levels (T2), SII is a protective factor for cardiotoxicity related to 5-FU but with a threshold effect.

16 November 2021 in Genetic Testing and Molecular Biomarkers
Verified
Journal Article
Closed access
WCWeiwei Chen
Weiwei Chen
WWWenling Wang
Wenling Wang
Objective: To identify serum microRNAs (miRNAs) correlated with response to neoadjuvant chemoradiation therapy (NCRT) in locally advanced rectal cancer (LARC) patients using in silico analyses and laboratory validation studies. Methods: The GSE68204 and GSE29298 data sets were analyzed to identify differentially expressed (DE) miRNAs in NCRT responders using the GEO2R Limma package within the R software suite. Then we used quantitative real-time polymerase chain reaction to detect the upregulated target miRNAs in the serum of 20 LARC patients. Logistic regression was used to evaluate the effect of serum miRNA level on response. Gene Ontology and pathway enrichment analyses were performed to predict the corresponding functions of the DE miRNAs. Correlation between the expression of the hub target genes and the abundance of tumor-infiltrating lymphocytes was further investigated. Results: hsa-miR-30e and hsa-miR-210 were verified to be upregulated in tumor tissues of NCRT responders. A subsequent liquid biopsy study revealed that serum level of miR-30e significantly increased in NCRT-responsive patients in comparison with nonresponders. Each additional unit of serum hsa-miR-30e level is associated with an increase of 2.47-fold in the incidence of response(odds ratio = 2.47, p = 0.0353). Nine hub target genes of hsa-miR-30e were enriched in pathways including immune regulation. The expression of these hub target genes was correlated with the abundance of tumor-infiltrating lymphocytes. Conclusion: In summary, hsa-miR-30e was determined to be upregulated in rectal cancer tissues of NCRT-responders. Further investigations showed that increased serum levels of hsa-miR-30e were associated with an effective NCRT response in LARC patients.

13 April 2021 in Research Square
Verified
Preprint
Open access
PDF file
WCWeiwei Chen
Weiwei Chen
HDHongmin Dong
Hongmin Dong
GWGang Wang
Gang Wang
JCJuan Chen
Juan Chen
WWWenling Wang
Wenling Wang
Background: Only 50-70% elderly colon cancer patients could complete a six-month postoperative chemotherapy. It is unknown whether a shorter duration of postoperative capecitabine-alone chemotherapy would not compromise the survival. We thus conducted this study to analyze the association between postoperative chemotherapy duration of capecitabine-alone regimen and cancer specific survival (CSS) in the surgery treated elderly colon cancer patients.Methods: We performed a retrospective cohort study in surgery treated stage III and high-risk stage II colon cancer patients aged >= 70 from two medical centers. Cox proportional hazard regression models were utilized to calculate crude and adjusted hazard ratios (HRs). The non-linear relationship between postoperative chemotherapy duration and CSS was analyzed through the restricted cubic spline regression analysis, and the threshold effect was calculated by the two-piece-wise Cox proportional hazard model.Results: A total of 1,217 surgery treated colon cancer patients between August 1, 2013 and September 1, 2019 were reviewed and 257 stage III and high-risk stage II patients aged >= 70 were finally enrolled. Postoperative chemotherapy with capecitabine was delivered in 114 patients and 143 cases only received surgery. The capecitabine duration was generally associated with a 11% risk decrease in death (HR=0.89, 95% confidence interval (CI) 0.82 - 0.96). Non-linearity exploration suggested a threshold effect of capecitabine duration on CSS in stage III disease. The HR for death was 0.79 (95% CI: 0.68 - 0.92) with duration <= 16 (week) while 1.34 (95% CI: 0.91 – 1.97) with duration > 16 (week).Conclusions: The postoperative capecitabine duration was significantly associated with CSS in elderly colon cancer. However, a threshold effect of capecitabine duration on survival may suggest a short-term chemotherapy could be an alternative for the conventional six-month regimen in the elderly stage III colon cancer.

1 August 2026 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
YGYuqi Gao
Yuqi Gao
QYQian Ye
Qian Ye
YZYunhuan Zhen
Yunhuan Zhen
YWYan Wang
Yan Wang
YWYi Wang
Yi Wang
WCWeiwei Chen
Weiwei Chen
Background: Over the past few years, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)— a compound from grilled or processed meats—has emerged as a major player in cancer development, especially colorectal cancer (CRC). This work dives into its potential links to CRC and uncovers the key genes that bridge this connection. Methods: We tapped into various databases to pinpoint target genes tied to PhIP and CRC, then ran protein-protein interaction (PPI) analyses for visualization. Next, we explored underlying mechanisms through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. To nail down predictions, we tested 107 machine learning pipelines and picked the best one, validating its accuracy and the core genes’ prognostic value across datasets. Next, molecular docking and dynamics simulations probed the interactions between these genes and PhIP. Finally, cell proliferation was assessed using Cell Counting Kit-8 (CCK-8) and 5-ethynyl-2’-deoxyuridine (EdU) assays, and polymerase chain reaction (PCR) was performed to validate the expression levels of the hub genes. Results: Our analysis identified 39 overlapping genes, from which a machine learning model (glmBoost + Enet) identified six candidate targets: CDK4, CEBPB, COMT, SOX9, TIMP1, and TOP2A. To prioritize these, a hierarchical screening framework was applied. Molecular docking and dynamics simulations identified CDK4, COMT, and TIMP1 as the most stable interactors with PhIP. Functional assays confirmed that PhIP treatment significantly enhanced the proliferation of CRC cells. Crucially, quantitative PCR (qPCR) validation in multiple CRC cell lines identified TIMP1 as the primary target, showing the most consistent and significant upregulation upon PhIP exposure. Conclusions: In essence, these genes drive PhIP is role in CRC, offering novel insights into its molecular pathways. This could reshape how we tackle food-related pollutants, paving the way for better prevention and targeted therapies.